BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 29128068)

  • 1. B Lymphoblastic Leukemia Minimal Residual Disease Assessment by Flow Cytometric Analysis.
    Shaver AC; Seegmiller AC
    Clin Lab Med; 2017 Dec; 37(4):771-785. PubMed ID: 29128068
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Role of CD81 and CD58 in minimal residual disease detection in pediatric B lymphoblastic leukemia.
    Tsitsikov E; Harris MH; Silverman LB; Sallan SE; Weinberg OK
    Int J Lab Hematol; 2018 Jun; 40(3):343-351. PubMed ID: 29500862
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of new markers for minimal residual disease monitoring in B-cell precursor acute lymphoblastic leukemia: CD73 and CD86 are the most relevant new markers to increase the efficacy of MRD 2016; 00B: 000-000.
    Tembhare PR; Ghogale S; Ghatwai N; Badrinath Y; Kunder N; Patkar NV; Bibi AR; Chatterjee G; Arora B; Narula G; Banawali S; Deshpande N; Amare P; Gujral S; Subramanian PG
    Cytometry B Clin Cytom; 2018 Jan; 94(1):100-111. PubMed ID: 27718302
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Improved Recognition of Hematogones From Precursor B-Lymphoblastic Leukemia by a Single Tube Flow Cytometric Analysis.
    Don MD; Lim W; Lo A; Cox B; Huang Q; Kitahara S; Lopategui J; Alkan S
    Am J Clin Pathol; 2020 May; 153(6):790-798. PubMed ID: 32068791
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Aberrant underexpression of CD81 in precursor B-cell acute lymphoblastic leukemia: utility in detection of minimal residual disease by flow cytometry.
    Muzzafar T; Medeiros LJ; Wang SA; Brahmandam A; Thomas DA; Jorgensen JL
    Am J Clin Pathol; 2009 Nov; 132(5):692-8. PubMed ID: 19846809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Flow cytometric detection of minimal residual disease in pre-cursor-B-acute lymphoblastic leukemia on the basis of phenotypic aberrancies on minor leukemic cell populations].
    Wu M; Sun XF; Xu ZM; Zhang XY; Li FR; Wang XG; Chen XL; Lin HQ; Wen HG; Sun X; Song TW
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2005 Aug; 13(4):557-62. PubMed ID: 16129033
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: how different are they from their normal counterparts?
    Sędek Ł; Bulsa J; Sonsala A; Twardoch M; Wieczorek M; Malinowska I; Derwich K; Niedźwiecki M; Sobol-Milejska G; Kowalczyk JR; Mazur B; Szczepański T
    Cytometry B Clin Cytom; 2014 Sep; 86(5):329-39. PubMed ID: 24845957
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Minimal residual disease analysis by eight-color flow cytometry in relapsed childhood acute lymphoblastic leukemia.
    Karawajew L; Dworzak M; Ratei R; Rhein P; Gaipa G; Buldini B; Basso G; Hrusak O; Ludwig WD; Henze G; Seeger K; von Stackelberg A; Mejstrikova E; Eckert C
    Haematologica; 2015 Jul; 100(7):935-44. PubMed ID: 26001791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD304/neuropilin-1 is a very useful and dependable marker for the measurable residual disease assessment of B-cell precursor acute lymphoblastic leukemia.
    Gudapati P; Khanka T; Chatterjee G; Ghogale S; Badrinath Y; Deshpande N; Patil J; Narula G; Shetty D; Banavali S; Patkar NV; Gujral S; Subramanian PG; Tembhare PR
    Cytometry B Clin Cytom; 2020 Jul; 98(4):328-335. PubMed ID: 31944572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Overexpression of CD49f in precursor B-cell acute lymphoblastic leukemia: potential usefulness in minimal residual disease detection.
    DiGiuseppe JA; Fuller SG; Borowitz MJ
    Cytometry B Clin Cytom; 2009 Mar; 76(2):150-5. PubMed ID: 18831072
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia.
    Verbeek MWC; van der Velden VHJ
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732101
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Significance of CD34/CD123 expression in detection of minimal residual disease in B-ACUTE lymphoblastic leukemia in children.
    Zeidan MA; Kamal HM; El Shabrawy DA; Esh AM; Sattar RH
    Blood Cells Mol Dis; 2016 Jul; 59():113-8. PubMed ID: 27282579
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A High-Sensitivity 10-Color Flow Cytometric Minimal Residual Disease Assay in B-Lymphoblastic Leukemia/Lymphoma Can Easily Achieve the Sensitivity of 2-in-10
    Tembhare PR; Subramanian Pg PG; Ghogale S; Chatterjee G; Patkar NV; Gupta A; Shukla R; Badrinath Y; Deshpande N; Narula G; Rodrigues P; Girase K; Dhaliwal D; Prasad M; Shetty D; Banavali S; Gujral S
    Cytometry B Clin Cytom; 2020 Jan; 98(1):57-67. PubMed ID: 31197916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Flow cytometric minimal residual disease assessment in B-cell precursor acute lymphoblastic leukaemia patients treated with CD19-targeted therapies - a EuroFlow study.
    Verbeek MWC; Buracchi C; Laqua A; Nierkens S; Sedek L; Flores-Montero J; Hofmans M; Sobral de Costa E; Nováková M; Mejstrikova E; Barrena S; Kohlscheen S; Szczepanowski M; Kulis J; Oliveira E; Jugooa R; de Jong AX; Szczepanski T; Philippé J; van Dongen JJM; Orfao A; Brüggemann M; Gaipa G; van der Velden VHJ
    Br J Haematol; 2022 Apr; 197(1):76-81. PubMed ID: 34881427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel flow cytometric assay for detection of residual disease in patients with B-lymphoblastic leukemia/lymphoma post anti-CD19 therapy.
    Cherian S; Miller V; McCullouch V; Dougherty K; Fromm JR; Wood BL
    Cytometry B Clin Cytom; 2018 Jan; 94(1):112-120. PubMed ID: 27598971
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Flow cytometric assessment for minimal/measurable residual disease in B lymphoblastic leukemia/lymphoma in the era of immunotherapy.
    Chen X; Gao Q; Roshal M; Cherian S
    Cytometry B Clin Cytom; 2023 May; 104(3):205-223. PubMed ID: 36683279
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Automated Flow Cytometric MRD Assessment in Childhood Acute B- Lymphoblastic Leukemia Using Supervised Machine Learning.
    Reiter M; Diem M; Schumich A; Maurer-Granofszky M; Karawajew L; Rossi JG; Ratei R; Groeneveld-Krentz S; Sajaroff EO; Suhendra S; Kampel M; Dworzak MN;
    Cytometry A; 2019 Sep; 95(9):966-975. PubMed ID: 31282025
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Deciphering stage 0 hematogones by flow cytometry in follow-up bone marrow samples of pediatric B-Acute lymphoblastic leukemia cases: A potential mimicker of residual disease after anti CD19 therapy.
    Ramalingam TR; Vaidhyanathan L; Muthu A; Swaminathan VV; Uppuluri R; Raj R
    Cytometry B Clin Cytom; 2024 Mar; 106(2):92-98. PubMed ID: 38243626
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The application of CD73 in minimal residual disease monitoring using flow cytometry in B-cell acute lymphoblastic leukemia.
    Wang W; Gao L; Li Y; Li ZL; Gong M; Huang FZ; Chen YR; Zhang CX; Gao YY; Ma YG
    Leuk Lymphoma; 2016 May; 57(5):1174-81. PubMed ID: 26436205
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunophenotypic expression and immunomodulation in minimal residual disease analysis of pediatric B acute lymphoblastic leukemia by high sensitive flow cytometry.
    Arumugam JR; Bommannan K; Radhakrishnan V; Sagar TG; Sundersingh S
    Leuk Lymphoma; 2022 Mar; 63(3):644-652. PubMed ID: 34727819
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.